Compare Main Street Capital Corporation (MAIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Main Street Capital Corporation trades at $53.67 (market cap $5.09B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Main Street Capital Corporation pays a 5.84% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MAIN | XBI | |
|---|---|---|
Market Cap | $5.09B | $10.11B |
Volume | 524,060 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $64.60 | $169.55 |
52-Week Low | $49.63 | $104.99 |
Typical Hold Time | 89 Days | 38 Days |
Enterprise Value | $7.54B | — |
Dividend Yield | 5.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $54.15, down slightly over the past day. The stock shows mixed technical signals with a bearish overall trend but oversold short-term RSI. Fundamentally, the company maintains strong profitability with an 80.77% net margin and a P/E of 10.94, though revenue is expected to decline in 2026. Recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026.
The outlook is cautious. Analyst consensus is a Hold with a $58.33 price target, implying modest upside. Risks include softening earnings and negative operating cash flow. The dividend remains well-covered, supporting income investors, but growth prospects appear limited near-term amid a bearish technical setup.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
